CLINICAL DEVELOPMENT OF THE NOVEL TUMOUR SELECTIVE CONTRAST AGENT SN132D
| Reference number | |
| Coordinator | SPAGO NANOMEDICAL AB (PUBL) - Spago Nanomedical AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | May 2018 - November 2018 |
| Status | Completed |
Purpose and goal
The objective of this project is to develop a business plan that includes a road map for the clinical development and subsequent commercialisation of SpagoPix. The objectives of the project include an assessment of the technical and market feasibility of commercialising new nanomaterial-based tumour selective MRI agent, SpagoPix.
Expected results and effects
Spago Nanomedical has analysed market data and conducted interviews with potential partners/KOLs. We have gained insights into market conditions including competitive landscape, challenges and opportunities of SpagoPix, and a deeper knowledge of the user needs, potential partners and stakeholders and how to reach them. We have developed a business plan guiding the clinical validation and commercialization efforts. The strategy is to perform a FIH-study for SpagoPix and thereafter acquire a strategic partner for continued clinical studies and commercialization.
Planned approach and implementation
The feasibility assessment has been performed using Strategic Business Planning Methodology - Strategic Business Review analysing market and competition, mapping out the value proposition for customers and defining clinical, economic and regulatory requirements to be considered in the Phase 2 Project. - Business Model Visioning developing the business model in line with the company’s vision, values, long-term development and revenue goals. - Business Plan Development and Formulation formulation of the final business strategy, business model and commercialisation plan.